Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says authorPatients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion and reduce appetite, and have been linked to reduced risks of heart attack, fewer drug overdoses and other health benefits. Continue reading...


11 h.
Science
ID: -5228336240584136920


Similar News expand_more


Science
Science
Science
Entertainment
Science
Science
Entertainment
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Space
Science
Science
Automotive
Science
Science
Science
Science
Entertainment
Entertainment
Entertainment
Entertainment
Science
Science
Science
Science
Real Estate
Science
Science
Science
Entertainment
Entertainment
Entertainment
Science
Science
Science
Science
Add Watch Country

arrow_drop_down